ArticleDoklady. Biochemistry and biophysics2025
Effect of Repair Gene Polymorphism on the Risk of Malignant Neoplasm Development after Chronic Radiation Exposure.
Article in Doklady. Biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficiency of DNA integrity repair processes after radiation exposure may depend on hereditary variations of repair genes caused by single nucleotide polymorphisms. Disturbances or even failure of repair processes trigger a chain of reactions leading to genome instability and oncogenic transformation of the cell. PURPOSE: To investigate the association of single nucleotide polymorphism in genes of nucleotide excision repair (ERCC2 rs13181, XPC rs2228001), AP site repair (APEX rs1130409), homologous recombination (XRCC3 rs861539), single-strand DNA break repair (XRCC1 rs25487), and double-strand DNA break repair (PARP rs1136410, XRCC4 rs2075685) with the risk of development of malignant neoplasms of various localizations in chronically exposed persons. MATERIALS AND
methodsThe study was perfomred in 861 individuals who were chronically exposed to low-dose low-rate radiation, 274 of which had malignant neoplasms (MN) of various localizations and 587 made up the comparison group (exposed persons without MN). The mean cumulative dose to red bone marrow (RBM) in the group of people with MN was 561.65 ± 25.31 mGy, while in the comparison group it was 543.14 ± 36.06 mGy. Genotyping of polymorphic loci rs13181, rs2228001, rs1130409, rs861539, rs25487, rs1136410, and rs2075685 was performed by real-time PCR. The association of polymorphic loci with the risk of MN development was determined by the odds ratio (OR) and 95% confidence interval (95% CI). A multifactor dimensionality reduction method was used to assess intergenic interactions.
resultsSingle-stranded DNA break repair gene (XRCC1) rs25487 polymorphism in accordance with the dominant model is associated with an increased risk of MN development in the combined group of the examined persons (OR = 1.79 (1.12‒2.87), p = 0.01) and in the Slavs group (OR = 2.26; 95% CI 1.06-4.81; p = 0.03). The rs861539 polymorphism of the gene involved in homologous recombination (XRCC3) in accordance with the recessive model is associated with a reduced risk of MN development both in the combined group of exposed persons (OR = 0.25 (0.15‒0.41); p < 0.00001) and separately in the group of the Slavs (OR = 0.28 (0.13‒0.60); p < 0.0001) and in the group of the Turkic people (OR = 0.22 (0.11‒0.44); p < 0.0001). The model of interfactorial interactions allowed us to establish a protective effect with respect to the risk of MN development in the carriers of polymorphic loci rs861539 of the XRCC3 gene and rs1130409 of the APEX1 gene (p < 0.001).
Indexed as
Identifiers
40216716What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.